THURSDAY, Jan. 12, 2023 (HealthDay News) — Six minutes of high-intensity exercise might prolong the lifespan of a healthy brain, perhaps delaying the start of Alzheimer’s and Parkinson’s diseases, a new, small study suggests. Researchers found that short but intense cycling increased the production of a protein called brain-derived neurotrophicContinue Reading

FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients. However, the FDA pointed to the drug’s benefits, as well. “Alzheimer’s disease immeasurably incapacitatesContinue Reading

THURSDAY, Jan. 5, 2023 (HealthDay News) — Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease. It’s also up for accelerated approval by the U.S. Food and Drug Administration, with a decision expected by Jan. 6. However, the drug hasContinue Reading

THURSDAY, Dec. 29, 2022 (HealthDay News) — The U.S. Food and Drug Administration’s approval process for the controversial Alzheimer’s drug Aduhelm was “rife with irregularities,” despite lingering doubts about the power of the pricey medication to slow the disease down, a Congressional report released Thursday claims. Actions the agency tookContinue Reading